Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Transcription profiling of skin samples from atopic dermatitis patients before and after treatment with cyclosporine A

ABSTRACT: After 2 and 12 weeks of treatment, we observed significant reductions of 51% and 72%, respectively, in SCORAD scores. Clinical improvements were associated with significant gene expression changes in lesional but also nonlesional skin, particularly reductions in levels of TH2-, TH22-, and some TH17-related molecules (ie, IL-13, IL-22, CCL17, S100As, and elafin/peptidase inhibitor 3), and modulation of epidermal hyperplasia and differentiation measures. Cyclosporine A (CsA)'s effects on AD skin pathology were evaluated by using gene expression and immunohistochemistry studies in baseline, week 2, and week 12 lesional and nonlesional biopsy specimens from 19 patients treated with 5 mg/kg/day CsA for 12 weeks.

ORGANISM(S): Homo sapiens

SUBMITTER: Mayte Suarez-Farinas 

PROVIDER: E-GEOD-58558 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.

Khattri Saakshi S   Shemer Avner A   Rozenblit Mariya M   Dhingra Nikhil N   Czarnowicki Tali T   Finney Robert R   Gilleaudeau Patricia P   Sullivan-Whalen Mary M   Zheng Xiuzhong X   Xu Hui H   Cardinale Irma I   de Guzman Strong Cristina C   Gonzalez Juana J   Suárez-Fariñas Mayte M   Krueger Jim G JG   Guttman-Yassky Emma E  

The Journal of allergy and clinical immunology 20140429 6

<h4>Background</h4>Atopic dermatitis (AD) is the most common inflammatory disease. Evolving disease models link changes in epidermal growth and differentiation to T(H)2/T(H)22 cytokine activation. However, these models have not been tested by in vivo suppression of T-cell cytokines. Cyclosporine (CsA) is an immunosuppressant that is highly effective for severe disease, but its mechanism in AD skin lesions has not been studied.<h4>Objective</h4>We sought to establish the ability of a systemic imm  ...[more]

Similar Datasets

Transcriptomics Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology
2014-06-17 | GSE58558 | GEO
Proteomics Microdialysis analysis of common inflammatory skin diseases highlights abnormalities in nonlesional skin of patients with atopic dermatitis
2024-08-22 | PXD050245 | Pride
Transcriptomics Discrimination of dysplastic nevi from common melanocytic nevi by cellular and molecular criteria
2014-08-01 | E-GEOD-53223 | biostudies-arrayexpress
Transcriptomics Defining an invasion signature at the leading edge of cutaneous squamous cell carcinoma (SCC): IL-24 driven MMP-7 and MMP-13 expression.
2013-04-30 | E-GEOD-42677 | biostudies-arrayexpress
Transcriptomics Transcription profiling of lesional and non-lesional skin from actopic dermititis patients and normal skin
2006-10-01 | E-GEOD-5667 | biostudies-arrayexpress
Transcriptomics Transcription data from Normal Skin and Nonlesional and Lesional Atopic Dermatitis/Eczema Skin
2006-10-01 | GSE5667 | GEO
Transcriptomics Pathologic Immune Pathways in Psoriasis are Rapidly Attenuated by Tofacitinib Treatment: A Randomized Phase 2 Study in Patients with Moderate to Severe Psoriasis
2016-06-30 | GSE69967 | GEO
Transcriptomics Human blood monocyte response to IL-17A in culture
2014-04-30 | E-GEOD-54884 | biostudies-arrayexpress
Transcriptomics Suppression of inflammation in psoriasis blood after IL-17 treatment with ixekizumab
2014-03-31 | E-GEOD-55201 | biostudies-arrayexpress
Transcriptomics Transcription profiling of human acne lesion vs. normal skin from acne and non acne patients
2008-06-14 | E-GEOD-6475 | biostudies-arrayexpress